NKGen CEO puts skin in the game, investing $2.6M to move biotech toward Alzheimer’s readout
NKGen Biotech CEO Paul Song, M.D., is putting his money where his mouth is, investing $2.65 million of his own cash to help accelerate the cash-strapped biotech’s phase 2 Alzheimer’s disease cell therapy trial.
NKGen Biotech CEO Paul Song, M.D., is putting his money where his mouth is, investing $2.65 million of his own cash to help accelerate the cash-strapped biotech’s phase 2 Alzheimer’s disease cell therapy trial.
